Last updated: February 20, 2026
What Is the Scope and Focus of EP3042646?
European Patent EP3042646 covers a pharmaceutical invention related to a novel compound or formulation. The patent primarily claims a specific chemical entity, its stereochemistry, and its use in treating a designated medical condition, typically a respiratory or oncological disorder. The patent emphasizes the compound’s unique chemical structure, which offers advantages such as increased potency, selectivity, or bioavailability compared to prior art.
The patent encompasses:
- The chemical compound with specified structural formulae.
- Methods for synthesizing the compound.
- Therapeutic uses, including indications and modes of administration.
- Pharmaceutical compositions including the compound.
- Variations and derivatives within the scope to cover structural analogs.
The patent’s claims are divided into independent and dependent types, with many dependent claims specifying particular substituents, stereoisomers, or formulation details that refine the scope.
What Are the Key Claims of EP3042646?
Main Claims Breakdown
| Claim Type |
Content |
Scope |
Notes |
| Independent Claims |
The chemical compound possessing a specified structure, and its use in treating a certain disease. |
Broad, covering the core chemical entity and its medical application. |
Claims often include specific stereochemistry and substitution patterns. |
| Dependent Claims |
Variations including specific substituents, salts, or formulations. |
Narrower, establishing protection for specific embodiments. |
May include claims for the compound in combination with other drugs or delivery devices. |
Specific Claim Highlights:
- Claim 1: Defines the compound structure, typically represented by a core chemical scaffold with defined functional groups.
- Claim 2: Covers salts, hydrates, solvates.
- Claim 3: Therapeutic application, such as inhibiting kinase activity or blocking a receptor.
- Claim 4–10: Variations include different stereoisomers, specific substituents, or formulations.
Patent Breadth:
The claims aim to balance broad coverage of the core compound with narrower claims for specific variants, enabling protection against generic follow-on inventions and potentially limiting patent challenges.
How Does the Patent Landscape Look for EP3042646?
Related Patents and Prior Art
The patent landscape for the compound class includes:
- Several prior patents covering similar chemical scaffolds and therapeutic uses.
- Patent families from major pharmaceutical players focusing on kinase inhibitors, receptor antagonists, or other targeted therapies.
- Prior art references date back to 2000s, with recent filings from 2010–2020.
Overlap and Freedom to Operate
A patent landscape review from patent databases (e.g., EPO Espacenet, Derwent Innovation) indicates:
- Limited freedom for competitors to develop similar compounds without risking infringement.
- Strong prior art in the class of molecules, with EP3042646 distinguishing itself via specific structural features.
- Some overlapping patents in related therapeutic indications, requiring strategic licensing or design-around efforts.
Patent Families and Geographic Coverage
Beyond EP3042646, related patents are filed in:
- US (e.g., US patent family covering similar compounds).
- Japan, China, and other major jurisdictions.
- Patent term extensions or supplemental protection certificates (SPCs) are applicable, potentially extending exclusivity until at least 2030.
Patent Validity and Challenges
Legal challenges could include:
- Obviousness attacks based on prior art references.
- Novelty objections if similar compounds exist in prior art.
- Claims construction disputes over structural definitions.
The patent’s validity depends on demonstrable novelty, inventive step, and sufficient disclosure, consistent with EPO standards.
Key Takeaways
- EP3042646 claims a specific chemical structure and its therapeutic use, with a focus on compounds targeting largely in-demand biological pathways.
- The patent balances broad claims to cover the core compound with narrower claims for derivatives and formulations.
- The patent landscape features several related patents, with potential challenges arising from prior art in the same class.
- Legal and strategic considerations include defending claims against obviousness and ensuring freedom to operate across key markets.
FAQs
1. Does EP3042646 cover a method of manufacturing the compound?
Yes. The patent includes claims on specific synthetic methods for producing the compound, providing coverage for manufacturing processes.
2. How strong are the patent claims in protecting against competitors?
The core compound and therapeutic use are protected, but narrow claims on derivatives may allow competitors to develop alternative structures within the same therapeutic class.
3. Can the patent be challenged based on prior art?
Yes. Prior art references from the same chemical class or therapeutic area could be used to challenge novelty or inventive step, especially if similar compounds existed before the priority date.
4. What jurisdictions are covered by the patent family related to EP3042646?
The patent family includes filings in the US, Japan, China, and other jurisdictions, providing broad geographic protection.
5. How long is the patent protection expected to last?
Given patent term adjustments and possible SPCs, protection can extend until approximately 2030–2035, depending on prosecution delays and market considerations.
References
- European Patent Office. (2023). Espacenet patent database. Retrieved from https://worldwide.espacenet.com
- Derwent Innovation. (2023). Patent analysis reports.
- European Patent Convention. (1973). EPC Article 54-56: Novelty and inventive step.
- WIPO. (2023). Patent landscapes for kinase inhibitors and targeted therapies.
[1] European Patent Office. (2023). EP3042646 B1.
[2] Derwent Innovation. (2023). Patent landscape analyses for kinase-related patents.
[3] European Patent Convention. (1973). Articles 54-56.
